PARK CITY, Utah–(BUSINESS WIRE)–BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and developer of the Revi® System, a patient-centric solution for urge urinary incontinence (UUI), announced today the publication of a comprehensive meta-analysis in the October issue of the peer-reviewed publication Advances in Therapy. “Sacral and Implantable Tibial…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
PITTSBURGH, Sept. 17, 2024 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) announced today the early tender results of the previously announced cash tender offer (the “Maximum Tender Offer”) of its subsidiary Utah […]
Q2 revenue growth of 15% year-over-year Q2 net income of $32.2 million and non-GAAP net income of $65.7 million Q2 net income margin of 12%; adjusted EBITDA margin of 42% Raising revenue and adjusted EBITDA […]
The first AI-designed drugs have ended with disappointment. Over the last year-plus, the first handful of molecules created by artificial intelligence have failed trials or been deprioritized. The AI companies behind these drugs brought them […]
Copyright © 2026 Biotech Networks
